Skip to main content

Advertisement

SpringerLink
Log in

The Role of Resistin in Inflammatory Myopathies

  • INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Both immune and non-immune mechanisms are involved in muscle damage and dysfunction occurring in idiopathic inflammatory myopathies (IIMs). Crosstalk among inflammatory cells, muscle and endothelial cells is essential in the pathogenesis of IIMs. Resistin, originally described as an adipokine linking obesity and insulin resistance in rodents, has been shown a pro-inflammatory molecule in humans. Besides its direct effect on production of several inflammatory mediators, resistin influences chemotaxis, migration, proliferation, cell survival, endothelial dysfunction and metabolism—all aspects implicated in the pathogenesis of IIMs. Up-regulation of resistin in muscle tissue and elevated serum resistin levels have been recently demonstrated in patients with IIMs. In addition, serum levels of resistin reflected global disease activity, including extramuscular organ involvement, in patients with this disease. However, there are currently not sufficient data to distinguish the features of resistin that cause injury of muscle tissue from those that promote muscle regeneration and repair. The aim of this review is therefore to summarize current knowledge about potential implication of resistin in idiopathic inflammatory myopathies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lundberg IE, Grundtman C. Developments in the scientific and clinical understanding of inflammatory myopathies. Arthritis Res Ther. 2008;10:220.

    Article  PubMed  Google Scholar 

  2. Li CK, Knopp P, Moncrieffe H, et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol. 2009;175:1030–40.

    Article  PubMed  CAS  Google Scholar 

  3. •• Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10:346–52. Systematic review of the literature on the pathogenesis and management of inflammatory muscle diseases.

    Article  PubMed  CAS  Google Scholar 

  4. Figarella-Branger D, Civatte M, Bartoli C, et al. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003;28:659–82.

    Article  PubMed  CAS  Google Scholar 

  5. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2009;21:610–6.

    Article  PubMed  Google Scholar 

  6. • Nasr R, Reed AM, Peterson EJ. Update: biomarkers for idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2012;24:609–15. Systematic review of new biomarkers for idiopathic inflammatory myopathies.

    PubMed  CAS  Google Scholar 

  7. • Gómez R, Conde J, Scotece M, et al. What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol. 2011;7:528–36. Systematic review of the literature on the role of adipokines in rheumatic diseases.

    Article  PubMed  Google Scholar 

  8. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.

    Article  PubMed  CAS  Google Scholar 

  9. Filková M, Haluzík M, Gay S, et al. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133:157–70.

    Article  PubMed  Google Scholar 

  10. Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50:2199–202.

    Article  PubMed  CAS  Google Scholar 

  11. Lu SC, Shieh WY, Chen CY, et al. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett. 2002;530:158–62.

    Article  PubMed  CAS  Google Scholar 

  12. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007;92:2272–9.

    Article  PubMed  CAS  Google Scholar 

  13. Lehrke M, Reilly MP, Millington SC, et al. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 2004;1:e45.

    Article  PubMed  Google Scholar 

  14. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–76.

    Article  PubMed  CAS  Google Scholar 

  15. Kaser S, Kaser A, Sandhofer A, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286–90.

    Article  PubMed  CAS  Google Scholar 

  16. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300:472–6.

    Article  PubMed  CAS  Google Scholar 

  17. Boström EA, Tarkowski A, Bokarewa M. Resistin is stored in neutrophil granules being released upon challenge with inflammatory stimuli. Biochim Biophys Acta. 2009;1793:1894–900.

    Article  PubMed  Google Scholar 

  18. Lee JH, Ort T, Ma K, et al. Resistin is elevated following traumatic joint injury and causes matrix degradation and release of inflammatory cytokines from articular cartilage in vitro. Osteoarthr Cartil. 2009;17:613–20.

    Article  PubMed  CAS  Google Scholar 

  19. • Zhang J, Lei T, Chen X, et al. Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway. Inflammation. 2010;33:25–33. Potential implication of resistin in inflammatory signaling pathways.

    Article  PubMed  Google Scholar 

  20. Bertolani C, Sancho-Bru P, Failli P, et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. J Pathol. 2006;169:2042–53.

    CAS  Google Scholar 

  21. Son YM, Ahn SM, Kim GR, et al. Resistin enhances the expansion of regulatory T cells through modulation of dendritic cells. BMC Immunol. 2010;11:33.

    Article  PubMed  Google Scholar 

  22. Silswal N, Singh AK, Aruna B, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NFkappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092–101.

    Article  PubMed  CAS  Google Scholar 

  23. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789–95.

    PubMed  CAS  Google Scholar 

  24. •• Tarkowski A, Bjersing J, Shestakov A, et al. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2010;14:1419–31. The original report demonstrating a receptor of resistin.

    Article  PubMed  CAS  Google Scholar 

  25. •• Filková M, Hulejová H, Kuncová K, et al. Resistin in idiopathic inflammatory myopathies. Arthritis Res Ther. 2012;14:R111. First report showing the role of resistin in idiopathic inflammatory myopathies.

    Article  PubMed  Google Scholar 

  26. Kim GT, Cho ML, Park YE, et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol. 2010;29:273–9.

    Article  PubMed  Google Scholar 

  27. Mackiewicz Z, Hukkanen M, Povilenaite D, et al. Dual effects of caspase-1, interleukin-1 beta, tumour necrosis factor-alpha and nerve growth factor receptor in inflammatory myopathies. Clin Exp Rheumatol. 2003;21:41–8.

    PubMed  CAS  Google Scholar 

  28. • Loell I, Lundberg IE. Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies? J Intern Med. 2011;269:243–57. Summary of molecular and histopathological mechanisms standing behind muscle weakness in idiopathic inflammatory myopathies.

    Article  PubMed  CAS  Google Scholar 

  29. Kirman I, Vainer B, Nielsen OH. Interleukin-15 and ist role in chronic inflammatory diseases. Inflamm Res. 1998;47:285–9.

    Article  PubMed  CAS  Google Scholar 

  30. Busquets S, Figueras MT, Meijsing S, et al. Interleukin-15 decreases proteolysis in skeletalmuscle: a direct effect. Int J Mol Med. 2005;16:471–6.

    PubMed  CAS  Google Scholar 

  31. Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45:270–80.

    Article  PubMed  CAS  Google Scholar 

  32. Kang S, Chemaly ER, Hajjar RJ, et al. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem. 2011;286:18465–73.

    Article  PubMed  CAS  Google Scholar 

  33. Calabro P, Samudio I, Willerson JT, et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110:3335–40.

    Article  PubMed  CAS  Google Scholar 

  34. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114:2903–10.

    PubMed  CAS  Google Scholar 

  35. Cohen G, Ilic D, Raupachova J, Hörl WH. Resistin inhibits essential functions of polymorphonuclear leukocytes. J Immunol. 2008;181:3761–8.

    PubMed  CAS  Google Scholar 

  36. Walcher D, Hess K, Berger R, et al. Resistin: a newly identified chemokine for human CD4-positive lymphocytes. Cardiovasc Res. 2010;85:167–74.

    Article  PubMed  CAS  Google Scholar 

  37. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res. 2006;69:76–85.

    Article  PubMed  CAS  Google Scholar 

  38. Ding Q, Chai H, Mahmood N, et al. Matrix metalloproteinases modulated by protein kinase Cε mediate resistin-induced migration of human coronary artery smooth muscle cells. J Vasc Surg. 2011;53:1044–51.

    Article  PubMed  Google Scholar 

  39. Shyu KG, Lien LM, Wang BW, et al. Resistin contributes to neointimal formation via oxidative stress after vascular injury. Clin Sci (Lond). 2011;120:121–9.

    Article  CAS  Google Scholar 

  40. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269–85.

    Article  PubMed  CAS  Google Scholar 

  41. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res. 2006;70:146–57.

    Article  PubMed  CAS  Google Scholar 

  42. Wu WT, Chen CN, Lin CI, et al. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology. 2005;146:3387–400.

    Article  PubMed  CAS  Google Scholar 

  43. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108:736–40.

    Article  PubMed  CAS  Google Scholar 

  44. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415–9.

    Article  PubMed  CAS  Google Scholar 

  45. Hung HF, Wang BW, Chang H, et al. The molecular regulation of resistin expression in cultured vascular smooth muscle cells under hypoxia. J Hypertens. 2008;26:2349–60.

    Article  PubMed  CAS  Google Scholar 

  46. •• Chemaly ER, Hadri L, Zhang S, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol. 2011;51:144–55. The role of resistin in multiple mechanisms of cell behaviour and organ homeostasis.

    Article  PubMed  CAS  Google Scholar 

  47. Chen C, Jiang J, Lü JM, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2010;299:H193–201.

    Article  PubMed  CAS  Google Scholar 

  48. Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep. 2001;3:334–45.

    Article  PubMed  CAS  Google Scholar 

  49. Niederwanger A, Kranebitter M, Ciardi C, et al. Resistin impairs basal and insulin-induced glycogen synthesis by different mechanisms. Mol Cell Endocrinol. 2007;263:112–9.

    Article  PubMed  CAS  Google Scholar 

  50. Palanivel R, Maida A, Liu Y, et al. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia. 2006;49:183–90.

    Article  PubMed  CAS  Google Scholar 

  51. Jørgensen SB, Honeyman J, Oakhill JS, et al. Oligomeric resistin impairs insulin and AICAR-stimulated glucose uptake in mouse skeletal muscle by inhibiting GLUT4 translocation. Am J Physiol Endocrinol Metab. 2009;297:E57–66.

    Article  PubMed  Google Scholar 

  52. Fan HQ, Gu N, Liu F, et al. Prolonged exposure to resistin inhibits glucose uptake in rat skeletal muscles. Acta Pharmacol Sin. 2007;28:410–6.

    Article  PubMed  CAS  Google Scholar 

  53. Moon B, Kwan JJ, Duddy N, et al. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab. 2003;285:E106–15.

    PubMed  CAS  Google Scholar 

  54. Schaffler A, Ehling A, Neumann E, et al. Adipocytokines in synovial fluid. JAMA. 2003;290:1709–10.

    Article  PubMed  Google Scholar 

  55. Senolt L, Housa D, Vernerová Z, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis. 2007;66:458–63.

    Article  PubMed  CAS  Google Scholar 

  56. Migita K, Maeda Y, Miyashita T, et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006;24:698–701.

    PubMed  CAS  Google Scholar 

  57. Forsblad d'Elia H, Pullerits R, Carlsten H, et al. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford). 2008;47:1082–7.

    Article  Google Scholar 

  58. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother. 2008;9:1121–8.

    Article  PubMed  CAS  Google Scholar 

  59. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:311–6.

    PubMed  CAS  Google Scholar 

  60. Klaasen R, Herenius MM, Wijbrandts CA, et al. Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis. 2012;71:1510–6.

    Article  PubMed  CAS  Google Scholar 

  61. Almehed K, d'Elia HF, Bokarewa M, et al. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R15.

    Article  PubMed  Google Scholar 

  62. Boström EA, d'Elia HF, Dahlgren U, et al. Salivary resistin reflects local inflammation in Sjögren’s syndrome. J Rheumatol. 2008;35(10):2005–11.

    PubMed  Google Scholar 

  63. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342–50.

    Article  PubMed  CAS  Google Scholar 

  64. Corbetta S, Angioni R, Cattaneo A, et al. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol. 2006;154:83–6.

    Article  PubMed  CAS  Google Scholar 

  65. Kocabas H, Kocabas V, Buyukbas S, et al. The serum levels of resistin in ankylosing spondylitis patients: a pilot study. Rheumatol Int. 2012;32:699–702.

    Article  PubMed  CAS  Google Scholar 

  66. Hulejová H, Levitová A, Kuklová M, et al. No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clin Rheumatol. 2012;31:67–71.

    Article  PubMed  Google Scholar 

  67. Pehlivan Y, Onat AM, Ceylan N, et al. Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis. 2012;15:374–9.

    Article  PubMed  CAS  Google Scholar 

  68. Gheita TA, El-Gazzar II, El Shazly RI, et al. Elevated serum resistin in juvenile idiopathicarthritis: relation to categories and disease activity. J Clin Immunol. 2012 Aug 11. [Epub ahead of print].

  69. • Boström EA, Ekstedt M, Kechagias S, et al. Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. Scand J Immunol. 2011;74:463–70. Association between resistin and autoantibodies in inflammatory diseases.

    Article  PubMed  Google Scholar 

  70. Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2004;43(1):49–54.

    Article  CAS  Google Scholar 

  71. Lundberg IE. New possibilities to achieve increased understanding of disease mechanisms in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2002;14:639–42.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by Ministry of Health Czech Republic (Research Project No. 00023728) and SVV (262512).

Conflict of Interest

Mária Filková declares no conflict of interest.

Ladislav Šenolt declares no conflict of interest.

Jiří Vencovský declares no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Na Slupi 4, 128 50, Prague 2, Czech Republic

    Mária Filková, Ladislav Šenolt & Jiří Vencovský

Authors
  1. Mária Filková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ladislav Šenolt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiří Vencovský
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ladislav Šenolt.

Additional information

This article is part of the Topical Collection on Inflammatory Muscle Disease

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filková, M., Šenolt, L. & Vencovský, J. The Role of Resistin in Inflammatory Myopathies. Curr Rheumatol Rep 15, 336 (2013). https://doi.org/10.1007/s11926-013-0336-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-013-0336-0

Keywords

Search

Navigation